Clincosm LogoSign in Get a demo

Ocular Imaging With Spectral Domain Optical Coherence Tomography

Sponsor
Yonsei University (Other)
Overall Status
Unknown status
CT.gov ID
NCT00926549
Collaborator
(none)
300
Enrollment
1
Location
1
Arm
4
Duration (Months)
74.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to analyze macular retinal thickness and macular volume using the spectral domain - optical coherence tomography (SD-OCT) in normal eyes and in eyes with various ocular diseases.

Condition or Disease Intervention/Treatment Phase
  • Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
 N/A

Detailed Description

Assessment of macular thickness is important for the treatment and follow-up of a variety of ocular diseases. The introduction of optical coherence tomography (OCT) has enabled clinicians to reliably detect small changes in macular thickness and to quantitatively evaluate the efficacy of different therapeutic modalities. In this study using the spectral domain-OCT, we examined the variations of macular retinal thickness and macular volume in normal eyes and in eyes with various ocular diseases.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Posterior and Anterior Ocular Imaging With Spectral Domain Optical Coherence Tomography
Study Start Date :
May 1, 2009
Anticipated Primary Completion Date :
Sep 1, 2009
Anticipated Study Completion Date :
Sep 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: spectral domain-OCT

Spectral domain-OCT scanning performed.

Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
macular cube scanning
Other Names:
  • Cirrus™ HD-OCT, Carl Zeiss Meditec AG

    		•

    Outcome Measures

    Primary Outcome Measures

    1. macular retinal thickness and volume [3 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • normal eyes

    • myopic eyes

    • hypermetropic eyes

    Exclusion Criteria:

    • systemic illness

    • cataract

    • previous ocular trauma or surgery(other than cataract surgery or refractive surgeries)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Yonsei University College of Medicine, Gangnam Severance Hospital Seoul Korea, Republic of 135-720

    Sponsors and Collaborators

    • Yonsei University

    Investigators

    • Principal Investigator: Sung Soo Kim, MD, PhD, Department of Ophthalmology, Yonsei University College of Medicine, Gangnam Severance Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00926549
    Other Study ID Numbers:
    • 3-2008-0048
    First Posted:
    Jun 23, 2009
    Last Update Posted:
    Jun 23, 2009
    Last Verified:
    Jun 1, 2009
    Keywords provided by , ,
    spectral domain-OCT
    macular thickness
    myopia
    hypermetropia
    normal
    Additional relevant MeSH terms:
    Myopia
    Hyperopia

    Study Results

    No Results Posted as of Jun 23, 2009